Abstract
Whereas most AIDS-related neurologic disorders have reduced incidence since HAART therapy was introduced, we find that the incidence of progressive multifocal leukoencephalopathy (PML) did not significantly differ between the pre-HAART and the HAART period (OR 0.78; 95% CI 0.41–1.50). These findings were confirmed by the preliminary results of the Italian Register Investigative Neuro AIDS (IRINA) Study, a prospective multicenter study started in January 2000, which showed that PML was the second most frequently diagnosed neurologic disorder after TE. A similar proportion of cases were found in HAART-naöve and HAART-experienced patients in our experience. PML was more common in the presence of HIV RNA > 500 copies/ml. Most of the cases occurring in HAART-exposed patients developed within the first 6 months of therapy. As others have reported, we find a prolonged survival in PML subjects prescribed HAART (245 days in the group treated with HAART versus 66 days in the group not treated with HAART; P at log rank = 0.001). However despite the survival benefit, AIDS-associated PML still has a serious prognosis. In fact, PML had the lowest 1-year survival probability of any cerebral disorder in our study (P = 0.0005). Our findings also confirm that CSF JCV DNA burden at baseline is a useful prognostic indicator with a threshold of 4.7 log10 JCV copies/ml (P at log rank = 0.01) in our experience. CSF JCV DNA load at 4 weeks of follow-up and clearance of JCV-DNA from CSF are associated with a better neurologic outcome and a longer survival.
Similar content being viewed by others
References
Ammassari A, Cingolani A, Pezzotti P, De Luca A, Murri R, Giancola ML, Larocca LM, Antinori A (2000). AIDS-related focal brain lesions in the era of highly active antiretroviral therapy. Neurology 55: 1194–1200.
Antinori A, Ammassari A, Cinque P, Toma L, Govoni A, Soldani F, Giancola ML, Grisetti S, Pierotti C, Fausti C, Finazzi MG, Bini T, Del Grosso B, Cristiano L, Corsi P, Fasulo G, Mena M, Guaraldi G, Arcidiacono MI, Monno L, Gigli B, Fibbia GC, Gentile M, Mastroianni A, Speranza F, d’Arminio Monforte A, Rezza G, Ippolito G (2001a). Shift of prevalence and selected characteristics in HIV-1 related neurologic disorders in HAART era: data from Italian Register Investigative Neuro AIDS (IRINA). 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, February 4–8, 2001 (Abstract 8).
Antinori A, Giancola ML, Soldani F, Grisetti S, Galgani S, Tozzi V, Gigli B, Gentile M, Busi E, Martini F, Calcaterra S, Girardi E, Ippolito G (2001b). Long term survival in HIV-1 infected patients with neurological disorders treated with HAART: analysis of clinical, immunological and virological predictors. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, February 4–8, 2001 (Abstract 599).
Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, Katlama C, Debre P, Leibowitch J (1997). Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277: 112–116.
Beck EJ, Mandalia S, Williams I, Power A, Newson R, Molesworth A, Barlow D, Easterbrook P, Fisher M, Innes J, Kinghorn G, Mandel B, Pozniak A, Tang A, Tomlinson D for the National Prospective Monitoring System Steering Group (1999). Decreasedmorbidity and use of hospital services in English HIV-infected individuals with increased uptake of antiretroviral therapy 1996–1997. AIDS 13: 2157–2164.
Berger JR, Kaszovitz B, Donovan Post MJ, Dickinson G (1987). Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. Ann Intern Med 107: 78–87.
Berger JR, Levy RM, Flomenhoft D, Dobbs M (1998). Predictive factors for prolonged survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy. Ann Neurol 44: 341–349.
Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski S, Helm EB (1997). Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 11: 1731–1738.
Cinque P, Casari S, Bertelli D (1998). Progressive multifocal leukoencephalopathy, HIV, and Highly Active Antiretroviral Therapy. N Engl J Med 339: 848–849.
Clifford DB, Yiannoutsos C, Glicksman M, Simpson DM, Singer EJ, Piliero PJ, Marra CM, Francis GS, McArthur JC, Tyler KL, Tselis AC, Hyslop NE (1999). HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology 52: 623–625.
Collazos J, Mayo J, Martinez E, Blanco MS (1999). Contrast-enhancing progressive multifocal leukoencephalopathy as an immune reconstitution event in AIDS patients. AIDS 13: 1426–1428.
d’Arminio Monforte A, Duca PG, Vago L, Grassi MP, Moroni M (2000). Decreasing incidence of CNS AIDS-defining events associated with antiretroviral therapy. Neurology 54: 1856–1859.
De Luca A, Giancola ML, Ammassari A, Grisetti S, Paglia MG, Gentile M, Cingolani A, Murri R, Liuzzi G, d’Arminio Monforte A, Antinori A (2000). The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy. J Infect Dis 182: 1077–1083.
De Luca A, Giancola ML, Cingolani A, Ammassari A, Gillini L, Murri R, Antinori A (1999). Clinical and virological monitoring during treatment with intrathecal cytarabine in patients with AIDS-associated progressive multifocal leukoencephalopathy. Clin Infect Dis 28: 624–628.
Dworkin MS, Wan PC, Hanson DL, Jones JL, and the Adult and Adolescent Spectrum of HIV Disease Project (1999). Progressive multifocal leukoencephalopathy: improved survival of human immunodeficiency virus-infected patients in the protease inhibitor era. J Infect Dis 180: 621–625.
Ellis RJ, Hsia K, Spector SA, Nelson JA, Heaton RK, Wallace MR, Abramson I, Atkinson H, Grant I, McCutchan JA, and the HIV Neurobehavioral Research Center Group (1997). Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. Ann Neurol 42: 679–688.
Fong IW, Toma E, and the Canadian PML Study Group (1995). The natural history of progressive multifocal leukoencephalopathy in patients with AIDS. Clin Infect Dis 20: 1305–1310.
Gasnault J, Taoufik Y, Goujard C, Kousignian P, Abbed K, Boue F, Dussaix E, Delfraissy JF (1999). Prolonged survival without neurological improvement in patients with AIDS-related progressive multifocal leukoencephalopathy on potent combined antiretroviral therapy. J NeuroVirol 5: 421–429.
Giancola ML, Tartaglione T, Ammassari A, Settecasi C, Cingolani A, Larussa D, Murri R, De Luca A (2000). Neurological and virologic predictors of survival in AIDS-associated progressive multifocal leukoencephalopathy (PML): the role of HAART. XIII International Conference on AIDS. Durban, July 9–14, 2000. (Abstract TuOrB358.)
Giudici B, Vaz B, Bossolasco S, Casari S, Brambilla AM, Luke W, Lazzarin A, Weber T, Cinque P (2000). Highly Active Antiretroviral Therapy and progressive multifocal leukoencephalopathy: effects on cerebrospinal fluid markers of JC virus replication and immune response. Clin Infect Dis 30: 95–99.
Koralnik IJ, Boden D, Mai VX, Lord CI, Letvin NL (1999). JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy. Neurology 52: 253–260.
Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, Battegay M, Vernazza P, Bernasconi E, Opravil M, Kaufmann D, Sudre P, Francioli P, Telenti A, and the Swiss Cohort Study (1999). AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 282: 2220–2226.
Mayo J, Collazos J, Martinez E (1998). Progressive multifocal leukoencephalopathy following initiation of highly active antiretroviral therapy. AIDS 12: 1720–1722.
Pallella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD, and the HIV Outpatient Study Investigators (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 338: 853–860.
Sacktor N, Lyles RH, Skolasky R, Kleeberger C, Seines OA, Miller EN, Becker JT, Cohen B, McArthur JC, and the Multicenter AIDS Cohort Study (2001). HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990–1998. Neurology 56: 257–260.
Tantisiriwat W, Tebas P, Clifford DB, Powderly J, Fichtenbaum CJ (1999). Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy. Clin Infect Dis 28: 1152–1154.
Taoufik Y, Delfraissy JF, Gasnault J (2000). Highly active antiretroviral therapy does not improve survival of patients with high JC virus load in the cerebrospinal fluid at progressive multifocal leukoencephalopathy diagnosis. AIDS 14: 758–759.
Taoufik Y, Gasnault J, Karaterki A, Ferey MP, Marchadier E, Goujard C, Lannuzel A, Delfraissy JF, Dussaix E (1998). Prognostic value of JC virus load in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy. J Infect Dis 178: 1816–1820.
Tassie JM, Gasnault J, Bentata M, Deloumeaux J, Boué F, Billaud E, Costagliola D, and the Clinical Epidemiology Group from the French Hospital Database on HIV (1999). Survival improvement of AIDS-related progressive multifocal leukoencephalopathy in the era of protease inhibitors. AIDS 13: 1881–1887.
Yiannoutsos CT, Major EO, Curfman B, Jensen PN, Gravell M, Hou J, Clifford D, Hall CD (1999). Relation of JC virus DNA in the cerebrospinal fluid to survival in acquired immunodeficiency syndrome patients with biopsyproven progressive multifocal leukoencephalopathy. Ann Neurol 45: 816–820.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Antinori, A., Ammassari, A., Giancola, M.L. et al. Epidemiology and prognosis of AIDS-associated progressive multifocal leukoencephalopathy in the HAART era. Journal of NeuroVirology 7, 323–328 (2001). https://doi.org/10.1080/13550280152537184
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1080/13550280152537184